Pharmacy staff opinions regarding diabetic retinopathy screenings in the community setting: Findings from a brief survey

American Health and Drug Benefits

Volumn 6, Issue 9, 2013, Pages

  Law, Miranda G ^a   Komura, Stephanie ^a   Murchison, Ann P ^b   Pizzi, Laura T ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b WILLS EYE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL PHARMACY; COMMUNITY CARE; DIABETIC RETINOPATHY; HEALTH CARE PERSONNEL; HEALTH SURVEY; HUMAN; MASS SCREENING; OUTCOME ASSESSMENT; PATIENT CARE; PHARMACIST; PILOT STUDY; PUBLIC HEALTH; QUESTIONNAIRE;

EID: 84894093612     PISSN: 19422962     EISSN: 19422970     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Fraser CE, D'Amico DJ. Classification and clinical features of diabetic retinopathy. UpToDate. www.uptodate.com/contents/classification-and-clinical-features-of-diabetic-retinopathy. Accessed March 4, 2012.
2. Congdon N, O'Colmain B, Klaver CC, et al; For the Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122:477-485.
3. National Eye Institute. Facts about diabetic retinopathy. Updated June 2012. www.nei.nih.gov/health/diabetic/retinopathy.asp. Accessed November 13, 2013.
4. Lee PP, Feldman ZW, Ostermann J, et al. Longitudinal prevalence of major eye diseases. Arch Ophthalmol. 2003;121:1303-1310.
5. Kempen JH, O'Colmain BJ, Leske MC, et al; For the Eye Diseases Prevalence Research Group. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol. 2004;122:552-563.
6. The Foundation of the American Academy of Ophthalmology. Diabetic retinopathy summary benchmark-November 2008. www.aaofoundation.org/hoskins/QEC-Content-Display.cfm?fuseaction=display&link=ea5c6d25-2ab9-4398-b00b8efcb8cc5bc7ion=SummaryBenchmarks. Accessed October 17, 2013.
7. American Diabetes Association. Diabetic retinopathy. Diabetes Care. 2000;23 (suppl 1):S73-S76.
8. Schoenfeld ER, Greene JM, Wu SY, Leske MC. Patterns of adherence to diabetes vision care guidelines: baseline findings from the Diabetic Retinopathy Awareness Program. Ophthalmology. 2001;108:563-571.
9. Zhang X, Saaddine JB, Lee PP, et al. Eye care in the United States: do we deliver to high-risk people who can benefit most from it? Arch Ophthalmol. 2007;125:411-418.
10. Klein R, Klein BE, Moss SE. Epidemiology of proliferative diabetic retinopathy. Diabetes Care. 1992;15:1875-1891.
11. Thomas G, Humphris G, Ozakinci G, et al. A qualitative study of pharmacists' views on offering chlamydia screening to women requesting Emergency Hormonal Contraception. BJOG. 2010;117:109-113.
12. Snella KA, Canales AE, Irons BK, et al. Pharmacy- and community-based screenings for diabetes and cardiovascular conditions in high-risk individuals. J Am Pharm Assoc (2003). 2006;46:370-377. Erratum in: J Am Pharm Assoc (Wash DC). 2006;46:666-667.
13. Winfrey C, Wortman S, Frede S, et al. Pharmacist-initiated peripheral arterial disease screening program in a community pharmacy setting. J Am Pharm Assoc (2003). 2011;51:373-377.
14. Fuller L, Conrad WF, Heaton PC, et al. Pharmacist-managed chronic obstructive pulmonary disease screening in a community setting. J Am Pharm Assoc (2003). 2012; 52:e59-e66.
15. Peterson GM, Fitzmaurice KD, Kruup H, et al. Cardiovascular risk screening program in Australian community pharmacies. Pharm World Sci. 2010;32:373-380.
16. Yuksel N, Majumdar SR, Biggs C, Tsuyuki RT. Community pharmacist-initiated screening program for osteoporosis: randomized controlled trial. Osteoporos Int. 2010; 21:391-398.
17. Johnson JF, Koenigsfeld C, Hughell L, et al. Bone health screening, education, and referral project in northwest Iowa: creating a model for community pharmacies. J Am Pharm Assoc (2003). 2008;48:379-387.